• LAST PRICE
    0.1860
  • TODAY'S CHANGE (%)
    Trending Down-0.0240 (-11.4286%)
  • Bid / Lots
    0.1785/ 6
  • Ask / Lots
    0.1900/ 1
  • Open / Previous Close
    0.2190 / 0.2100
  • Day Range
    Low 0.1742
    High 0.2190
  • 52 Week Range
    Low 0.0853
    High 3.5900
  • Volume
    753,624
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.21
TimeVolumeGRTX
09:32 ET91180.2104
09:33 ET191000.2103
09:35 ET33350.21
09:37 ET10000.2099
09:42 ET299020.2
09:46 ET6380.196
09:48 ET152000.203
09:50 ET12560.206
09:51 ET10000.2101
09:53 ET16500.2125
09:55 ET25000.2125
10:02 ET32310.1963
10:04 ET1860.1966
10:06 ET8590.204551
10:13 ET5000.2
10:18 ET147000.213
10:20 ET23000.2044
10:27 ET186670.1986
10:29 ET3870.1975
10:38 ET9780.1979
10:40 ET17000.198
10:56 ET3500.2021
10:58 ET5000.200949
11:00 ET10000.2027
11:02 ET1000.2027
11:03 ET58730.2028
11:07 ET9600.2024
11:18 ET4500.2008
11:20 ET10000.2001
11:23 ET1000.2008
11:25 ET2000.199201
11:27 ET12000.2008
11:32 ET18500.1991
11:34 ET8500.1992
11:52 ET1000.1992
12:01 ET2000.1996
12:06 ET7000.2028
12:14 ET173320.2014
12:15 ET1000.201
12:17 ET223430.198325
12:21 ET2000.1975
12:24 ET2930.1959
12:26 ET284300.191
12:28 ET61720.1881
12:30 ET38290.1894
12:32 ET3380.1887
12:33 ET401150.1881
12:37 ET2300.1857
12:39 ET74340.1857
12:42 ET2000.18645
12:44 ET7380.186
12:46 ET2000.186
12:50 ET5000.186
12:51 ET6000.18705
12:53 ET12510.188099
12:55 ET2170.186
12:57 ET15980.1848
01:00 ET3000.1881
01:02 ET3000.188
01:06 ET24180.1865
01:08 ET13040.1865
01:09 ET60380.1879
01:11 ET35000.188
01:18 ET1010.1881
01:22 ET10000.1881
01:26 ET50290.1908
01:27 ET20000.188
01:31 ET5980.1899
01:47 ET1050.1896
01:56 ET33230.1877
02:03 ET44620.1849
02:05 ET9410.1853
02:07 ET41760.1841
02:09 ET2200.1816
02:16 ET9980.1845
02:18 ET7740.1816
02:20 ET70000.1826
02:21 ET32110.18255
02:23 ET9650.1825
02:25 ET1000.1823
02:34 ET115330.1837
02:38 ET9000.18905
03:03 ET2930.1833
03:06 ET8280.1833
03:08 ET52690.1826
03:10 ET9050.1815
03:12 ET6390.1816
03:14 ET51450.1823
03:17 ET10260.1816
03:19 ET237060.1762
03:21 ET75010.1772
03:24 ET46680.1795
03:26 ET146800.1799
03:28 ET8290.1788
03:30 ET1090.1787
03:33 ET6170.1787
03:35 ET32570.1858
03:37 ET6000.1867
03:39 ET1000.1856
03:42 ET7000.1851
03:44 ET1140.1821
03:48 ET3720.1821
03:51 ET49370.1816
03:53 ET6000.1857
03:55 ET352150.185
03:57 ET357220.1858
04:00 ET260250.186
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGRTX
Galera Therapeutics Inc
10.1M
-0.1x
---
United StatesPHGE
Biomx Inc
9.8M
-0.3x
---
United StatesBUDZ
Weed Inc
9.7M
-19.7x
---
United StatesNDRA
ENDRA Life Sciences Inc
9.7M
-0.4x
---
United StatesHEPA
Hepion Pharmaceuticals Inc
10.5M
-0.2x
---
United StatesASLN
Aslan Pharmaceuticals Ltd
9.6M
-0.1x
---
As of 2024-02-25

Company Information

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a pipeline of therapeutic candidates to transform radiotherapy in cancer. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic in development for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) and for the reduction of esophagitis in patients with lung cancer. It has completed Phase III Reduction in Oral Mucositis with Avasopasem Manganese (ROMAN) trial of GC4419 for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC. Its second dismutase mimetic product candidate, rucosopasem manganese (GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

Contact Information

Headquarters
45 Liberty Blvd., Suite 230MALVERN, PA, United States 19355
Phone
610-725-1500
Fax
302-636-5454

Executives

Independent Chairman of the Board
Michael Powell
President, Chief Executive Officer, Director
J. Mel Sorensen
Chief Financial Officer, Secretary
Christopher Degnan
Chief Operating Officer
Robert Beardsley
Chief Legal & Compliance Officer and Secretary
Jennifer Stacey

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$10.1M
Revenue (TTM)
$0.00
Shares Outstanding
54.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.15
EPS
$-1.90
Book Value
$-3.83
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.